B12 Absorption Test Predicts Response To Year Of Oral Supplements
A secondary analysis published Sept. 21, 2026 in the European Journal of Clinical Nutrition reports that how well a person absorbs oral vitamin B12 on a short test predicts how their B12 status changes over a year of daily supplements, in 313 people from a B12-deficient rural Indian community.
Researchers analyzed 313 participants from the Pune Maternal Nutrition Study, a B12-deficient rural Indian community: 109 children (age 9, weight 21.9 kg, BMI 13.6), 108 mothers (age 30, weight 47.7 kg, BMI 19.3) and 96 fathers (age 37, weight 59.3 kg, BMI 21.4). All completed a short absorption test, the CobaSorb protocol, measuring the rise in plasma holotranscobalamin, the actively absorbed form of B12, after a test dose, then entered a 12-month double-blind trial of daily oral cyanocobalamin at 0, 2 or 10 micrograms, with or without 200 micrograms of folic acid. The holoTC rise was higher with the 2- and 10-microgram doses and lower in heavier participants, with exact differences not reported. Over 12 months, changes in plasma B12, homocysteine and a combined marker called 2cB12 tracked with baseline levels, absorption-test response, B12 dose and supplement compliance, again without specific numbers given.
12-Month Trial Tested B12 Doses Of 0, 2 Or 10 Micrograms In 313 People
HoloTC reflects the fraction of B12 actively delivered to cells, and homocysteine rises when B12-dependent enzymes lack fuel to clear it, so a drop signals the vitamin reaching its target tissues, the authors note. Heavier body weight likely diluted the effective dose per kilogram, which the authors say explains the smaller absorption-test rises in bigger participants. The findings suggest a short absorption test can flag who will respond weakly to a standard oral B12 dose and who may need more.
This was a secondary analysis of an existing trial, not one designed to test absorption prediction, and the abstract gives only the direction of these relationships, not exact effect sizes. The population studied was already B12-deficient rural Indian children and adults, so the pattern may not generalize to people with different diets or B12 status, and funding was not reported.
Data Panel
- Who
- 313 participants from the Pune Maternal Nutrition Study, a B12-deficient rural Indian community: 109 children (mean age 9, weight 21.9 kg, BMI 13.6), 108 mothers (age 30, weight 47.7 kg, BMI 19.3), and 96 fathers (age 37, weight 59.3 kg, BMI 21.4).
- Design
- Secondary analysis of a B12 absorption test (CobaSorb protocol) followed by a 12-month double-blind randomized controlled trial.
- Dose
- Daily oral cyanocobalamin at 0, 2, or 10 micrograms, plus folic acid at 0 or 200 micrograms.
- Primary result
- HoloTC rise during the absorption test was higher with the 2- and 10-microgram B12 doses and lower in participants with higher body weight; effect sizes not reported.
- Secondary
- Over 12 months, changes in plasma B12, homocysteine, and the combined 2cB12 indicator were positively predicted by baseline biomarker levels, absorption-test response, B12 dose, and supplement compliance; sizes not reported.
- Funding / conflicts
- Not reported.
Dr. Axe's Take
Poor response to a basic B12 tablet often comes down to absorption capacity and body size, not just whether someone took the pill. If a person has stayed on cyanocobalamin for months without any shift in energy or labs, the dose may simply be too low for their body. I look at methylcobalamin or hydroxocobalamin as forms worth trying when cyanocobalamin does not seem to work. I would also ask a doctor to track more than one B12-related marker over time, since a single snapshot can miss a slow response. Give any new B12 approach time before expecting blood work to change, since absorption and metabolic correction happen gradually.
— Dr. Axe